0001703057falseVancouverBC00017030572025-02-272025-02-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 27, 2025
__________________________________________
AbCellera Biologics Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
British Columbia001-39781Not Applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
150 W 4th Avenue
Vancouver, BC
V5Y 1G6
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o


Item 2.02    Results of Operations and Financial Condition
On February 27, 2025, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the year ended December 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 7.01    Regulation FD Disclosure
In connection with its earnings call on February 27, 2025, to discuss its results for the year ended December 31, 2024, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.
The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01    Financial Statements and Exhibits
(d)Exhibits
Exhibit
No.		Description
99.1
99.2
104Cover Page Interactive Data File (embedded as Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 27, 2025ABCELLERA BIOLOGICS INC.
 
By:/s/ Carl L. G. Hansen
Carl L. G. Hansen, Ph.D.
Chief Executive Officer and Director
(Principal Executive Officer)


NEWS RELEASE


AbCellera Reports Full Year 2024 Business Results

2/27/2025



VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“In 2024 we made significant progress in transitioning from a platform company to a clinical-stage biotech, including advancing our internal pipeline and completing significant investments in our capabilities. We also maintained our strong cash position, closing the year with over $800 million in available liquidity to execute on our strategy,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “As a result, we enter 2025 on track to initiate Phase 1 clinical trials for our first two programs, ABCL635 and ABCL575, and to start activities in our new clinical manufacturing facility.”

FY 2024 Business Summary
●Earned $28.8 million in total revenue.
●Generated a net loss of $162.9 million, compared to net loss of $146.4 million in 2023.
●Reached a cumulative total of 96 partner-initiated program starts with downstreams.
●Reporting the advancement of three additional molecules in the clinic, bringing the cumulative total to 16 molecules to have reached the clinic.

1

Key Business Metrics
Cumulative MetricsDecember 31, 2023December 31, 2024Change %
Partner-initiated program starts with downstreams879610 %
Molecules in the clinic131623 %

AbCellera started discovery on an additional nine partner-initiated programs with downstreams to reach a cumulative total of 96 partner-initiated program starts with downstreams in 2024 (up from 87 on December 31, 2023). AbCellera’s partners have advanced a cumulative total of 16 molecules into the clinic (up from 13 on December 31, 2023).

Discussion of FY 2024 Financial Results
●Revenue – Total revenue was $28.8 million, compared to $38.0 million in 2023. In both periods, the majority of revenues were research fees generated by our partnerships.
●Research & Development (R&D) Expenses – R&D expenses were $167.3 million, compared to $175.7 million in 2023, reflecting underlying continued growth in program execution, platform development, and investments in internal programs.
●Sales & Marketing (S&M) Expenses – S&M expenses were $12.8 million, compared to $14.2 million in 2023.
●General & Administrative (G&A) Expenses – G&A expenses were $72.7 million, compared to $61.0 million in 2023.
●Net Loss – Net loss of $162.9 million, or $(0.55) per share on a basic and diluted basis, compared to net loss of $146.4 million, or $(0.51) per share on a basic and diluted basis, in 2023.
●Liquidity – $652.9 million of total cash, cash equivalents, and marketable securities and approximately $186 million in available non-dilutive government funding, bringing total available liquidity to approximately $840 million to execute on AbCellera's strategy.
Q4 Highlights and Financial Results
●Abdera advanced ABD-147 into a Phase 1 clinical trial. AbCellera is a founding partner in Abdera, has a low-single-digit royalty stake in Abdera’s programs, and has a mid-single-digit equity ownership position.
●Reporting the advancement of two Trianni-license molecules into the clinic.
●Started one partner-initiated program with downstreams.
●Revenue for the fourth quarter of 2024 was $5.1 million, the majority of which was research fees generated by our partnerships, representing 18% of total revenue for 2024.
●Operating expenses totaled $77.8 million in the fourth quarter, or 23% of the total for 2024, and included investments made in co-development and internal programs.
2

●The net loss for the fourth quarter was $34.2 million, or $(0.12) per share, on a basic and diluted basis.

Conference Call and Webcast
AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).
The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.
3

About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

Definition of Key Business Metrics
We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops.
Partner-initiated program starts with downstreams represent the number of unique partner-initiated programs where we stand to participate financially in downstream success for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of the selection and initiation of projects by our partners and the resulting potential for near-term payments. Cumulatively, partner-initiated program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties (or royalty equivalents) in the mid- to long-term.
Molecules in the clinic represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has reached "open" status or has otherwise been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.

AbCellera Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
4

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Source: AbCellera Biologics Inc.

Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116
5

AbCellera Biologics Inc.
Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.)

Year ended December 31,
202220232024
Revenue:
Research fees$40,802 $35,556 $26,284 
Licensing revenue696 969 1,049 
Milestone payments900 1,500 1,500 
Royalty revenue443,026 — — 
Total revenue485,424 38,025 28,833 
Operating expenses:
Royalty fees66,436 — — 
Research and development(1)
107,879 175,658 167,259 
Sales and marketing(1)
11,270 14,180 12,779 
General and administrative(1)
55,485 60,999 72,711 
Depreciation, amortization, and impairment27,843 24,395 90,850 
Total operating expenses268,913 275,232 343,599 
Income (loss) from operations216,511 (237,207)(314,766)
Other (income) expense
Interest income(16,079)(42,247)(38,473)
Grants and incentives(10,554)(14,155)(13,620)
Other
4,045 (6,776)(62,278)
Total other income(22,588)(63,178)(114,371)
Net earnings (loss) before income tax239,099 (174,029)(200,395)
Income tax (recovery) expense80,580 (27,631)(37,538)
Net earnings (loss)$158,519 $(146,398)$(162,857)
Foreign currency translation adjustment(1,671)(329)(2,658)
Comprehensive income (loss)$156,848 $(146,727)$(165,515)
Net earnings (loss) per share
Basic$0.56 $(0.51)$(0.55)
Diluted$0.50 $(0.51)$(0.55)
Weighted-average common shares outstanding
Basic285,056,606289,166,486294,327,532
Diluted314,827,255289,166,486294,327,532

(1) Exclusive of depreciation, amortization, and impairment
6

AbCellera Biologics Inc.
Consolidated Balance Sheets
(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)
December 31, 2023December 31, 2024
Assets
Current assets:
Cash and cash equivalents$133,320 $156,325 
Marketable securities627,265 469,289 
Total cash, cash equivalents, and marketable securities760,585 625,614 
Accounts and accrued receivable30,590 33,616 
Restricted cash25,000 25,000 
Other current assets55,810 67,140 
Total current assets871,985 751,370 
Long-term assets:
Property and equipment, net287,696 340,429 
Intangible assets, net120,425 42,113 
Goodwill47,806 47,806 
Investments in equity accounted investees65,938 82,297 
Other long-term assets94,244 96,538 
Total long-term assets616,109 609,183 
Total assets$1,488,094 $1,360,553 
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and other current liabilities$49,580 $55,004 
Contingent consideration payable50,475 8,087 
Deferred revenue18,958 13,521 
Total current liabilities119,013 76,612 
Long-term liabilities:
Operating lease liability71,222 60,743 
Deferred revenue8,195 5,700 
Deferred government contributions95,915 149,893 
Contingent consideration payable4,913 — 
Deferred tax liability30,612 10,052 
Other long-term liabilities5,906 1,469 
Total long-term liabilities216,763 227,857 
Total liabilities335,776 304,469 
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2023 and December 31, 2024: 290,824,970 and 295,757,002 shares issued and outstanding at December 31, 2023 and December 31, 2024, respectively753,199 777,171 
Additional paid-in capital121,052 166,361 
Accumulated other comprehensive loss(1,720)(4,378)
Accumulated earnings279,787 116,930 
Total shareholders' equity1,152,318 1,056,084 
Total liabilities and shareholders' equity$1,488,094 $1,360,553 
7

AbCellera Biologics Inc.
Consolidated Statement of Cash Flows
(Expressed in thousands of U.S. dollars.)

December 31, 2022December 31, 2023December 31, 2024
Cash flows from operating activities:
Net earnings (loss)$158,519 $(146,398)$(162,857)
Cash flows from operating activities:
Depreciation of property and equipment8,953 12,758 12,537 
Amortization and impairment of intangible assets18,890 11,637 78,312 
Amortization of operating lease right-of-use assets5,259 6,499 6,149 
Stock-based compensation49,481 64,183 67,581 
Fair value (gain) loss on contingent consideration and investments3,091 (8,018)(64,727)
Other3,342 2,237 (19,708)
Changes in operating assets and liabilities:
Research fee and grant receivable(22,715)(45,933)(75,119)
Accrued royalties receivable129,171 9,273 — 
Income taxes (payable) receivable(88,609)30,464 6,651 
Accounts payable and accrued liabilities(2,094)(15,104)10,635 
Deferred revenue6,183 (13,976)(7,931)
Deferred grant income9,264 39,521 33,967 
Other assets(1,375)8,980 5,954 
Net cash provided by (used in) operating activities277,360 (43,877)(108,556)
Cash flows from investing activities:
Purchases of property and equipment(70,660)(76,947)(78,396)
Purchase of intangible assets(2,000)(560)— 
Purchase of marketable securities(763,982)(1,021,510)(765,086)
Proceeds from marketable securities510,631 910,937 937,882 
Receipt of grant funding16,434 25,311 35,708 
Investment in and loans to equity accounted investees(25,679)(13,690)(19,626)
Long-term investments and other assets(17,369)(44,649)10,927 
Net cash provided by (used in) investing activities(352,625)(221,108)121,409 
Cash flows from financing activities:
Payment of liability for in-licensing agreement and other(4,383)(1,234)(729)
Proceeds from long-term liabilities and exercise of stock options2,755 11,590 13,498 
Net cash provided by (used in) financing activities(1,628)10,356 12,769 
Effect of exchange rate changes on cash and cash equivalents(9,599)589 (2,617)
Increase (decrease) in cash and cash equivalents(86,492)(254,040)23,005 
Cash and cash equivalents and restricted cash, beginning of period501,142 414,650 160,610 
Cash and cash equivalents and restricted cash, end of period$414,650 $160,610 $183,615 
Restricted cash included in other assets3,115 2,290 2,290 
Total cash, cash equivalents, and restricted cash shown on the balance sheet$411,535 $158,320 $181,325 
Supplemental disclosure of non-cash investing and financing activities
Property and equipment in accounts payable5,868 13,625 12,767 
Right-of-use assets obtained in exchange for operating lease obligation50,694 1,199 1,898 
8
CO PY RI GH T © A BC EL LE RA FEBRUARY 27, 2025 FULL YEAR 2024 BUSINESS UPDATE

 
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. 2 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e

 
3 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e FULL YEAR 2024 RECAP Transitioning into a clinical-stage biotech. Completing Investments in Our Engine Building Internal Pipeline & Programs ● Put first 2 programs on track for Clinical Trial Application (CTA) submissions in Q2 2025 ● Advanced discovery pipeline of antibody drug programs with first-in-class or best-in-class potential ● Moved into new HQ ● Built Phase 1 clinical manufacturing and operations capabilities for launch in 2025 Reducing New Discovery Partnership Activity ● 2 new partnerships ● 1 partnership expansion in available liquidity to execute on our strategy~$840M

 
4 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Use our competitive advantage in antibody drug creation to build a pipeline of differentiated assets. STRATEGY

 
5 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Is there an opportunity for differentiation? Is there a clear development path? Is there a commercial opportunity with an unmet medical need? Do we like the science? Our platform supports multiple modalities including IgGs, ADCs and bispecifics. Our strategy is to look broadly for programs that have the highest potential ROI, without constraint by indication. We manage our portfolio and assess opportunities by asking the following questions: Pursue high-value opportunities across multiple indications and modalities. INTERNAL PIPELINE & PROGRAMS

 
6 CO PY RI GH T © A BC EL LE RA ● Potential first-in-class antibody in area of metabolic and endocrine conditions ● Expect differentiated safety profile vs small molecules ● Convenience and compliance with subcutaneous dosing schedule Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e ABCL635 Undisclosed Science DifferentiationCommercial Opp Development Path ● Pathway validated with small molecules ● High unmet need in large target population ● >$2B estimated market ● Clear clinical development path ● CTA* filing anticipated in Q2 2025 with safety and early efficacy data readout in 2026 * Clinical Trial Applications (CTAs) = Canadian equivalent to an Investigational New Drug (IND) submission INTERNAL PIPELINE & PROGRAMS

 
7 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e ● OX40L mechanism of action established in atopic dermatitis with a favourable safety profile ● High potential across multiple immunology and inflammation (I&I) indications (asthma, alopecia, HS, celiac etc.) ● Attractive pathway for development of combinations in I&I * Cantor Fitzgerald Estimate, September, 2024 ● Competitive space with two late stage programs targeting OX40L (amlitelimab) and OX40 (rocatilimab) ● ABCL575 expected to support Q12W or longer dosing schedule ● Atopic dermatitis is an $11B+* market, growing at over 25% ● Need for alternatives beyond IL-13 and IL-4/13 classes in both 1st line and 2nd line (more than 20%** of dupilumab patients discontinue) ● Potential of OX40L class across multiple indications is being evaluated ● Well-established clinical development path ● CTA*** filing anticipated in Q2 2025 with safety and PK in 2026 ** Spekhorst et al. JAMA Dermatol. 2022; 158(9): 1048 *** Clinical Trial Applications (CTAs) = Canadian equivalent to an Investigational New Drug (IND) submission ABCL575 OX40L Antagonist INTERNAL PIPELINE & PROGRAMS Science DifferentiationCommercial Opp Development Path

 
8 CO PY RI GH T © A BC EL LE RA MOLECULE TARGET THERAPEUTIC AREA STAGE ABCL635 Undisclosed GPCR or ion channel Metabolic & Endocrine Conditions ABCL575 OX40L Immunology & Inflammation Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e In 2025 we intend to submit CTAs* for our first 2 programs. * Clinical Trial Applications (CTAs) = Canadian equivalent to an Investigational New Drug (IND) submission CTA / IND-Enabling 2025 Q1 In progress CTA Submission 2025 Q2 Anticipated Phase I Readout 2026 Anticipated CTA / IND-Enabling 2025 Q1 In progress CTA Submission 2025 Q2 Anticipated Phase I Readout 2026 Anticipated 20+ discovery programs in the pipeline INTERNAL PIPELINE & PROGRAMS

 
9 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e In order to focus on our pipeline, we decreased new discovery partnership activity. new partnerships 2 AbbVie partnership expansion 1 Entered into first significant TCE partnership agreement based on T-Cell Engager platform: Entered into 3 partnership agreements in the first half of 2024: PARTNERING PORTFOLIO 2024 Partnering Activity T-Cell Engager Platform Activity partnership expansion 1

 
10 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Enter the clinic and initiate clinical manufacturing activities at new facility. ABCL635 Phase 1 clinical trials initiated in 2025 ABCL575 Phase 1 clinical trials initiated in 2025 Complete platform investments by the first half of the year Initiate activities at the new clinical manufacturing facility Nominate additional development candidate(s) for CTA-enabling studies 2025 PRIORITIES

 
11 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e We expect a number of key milestones in the next 18-24 months. CTA submissions anticipated in Q2 2025. If successful, initiation of Phase 1 clinical trials to follow: ● ABCL635 ● ABCL575 20+ internal programs in the pipeline: ● Expect steady flow of readouts on potentially first-in-class therapeutic antibodies Anticipate readout of Phase 1 clinical data: ● ABCL635 ● ABCL575 First 2 clinical data readouts in 2026 First 2 CTAs* & start of clinical trials in 2025 Intention to submit 1-3 INDs per year over next 5 years POTENTIAL MILESTONES * Clinical Trial Applications (CTAs) = Canadian equivalent to an Investigational New Drug (IND) submission

 
12 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 20 24 B us in es s U pd at e FULL YEAR 2024 FINANCIALS UPDATE

 
13 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e in total cash, cash equivalents, & marketable securities cumulative partner-initiated program starts with downstreams internal programs advanced into IND/CTA-enabling studies ~$650M 96 2 molecules in the clinic16 in available liquidity to execute on our strategy~$840M Continued progress on key business metrics and a strong cash position.

 
14 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e PARTNER-INITIATED PROGRAM STARTS WITH DOWNSTREAMS Cumulative # of MOLECULES IN THE CLINIC Cumulative # of Note: Showing year-end figures. Historical results are not necessarily indicative of future results. Notable Updates on Molecule This Quarter’s Update ABD-147 Advanced into Phase 1 trial Undisclosed (Trianni license) New, in Phase 1/2 trial GIGA-564 (Trianni license) New, in Phase 1 trial Continuing portfolio growth. MOLECULES IN THE CLINIC

 
15 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Partner-initiated programs continue to progress towards the clinic. PARTNER-INITIATED PROGRAMS WITH DOWNSTREAM PARTICIPATION*Cumulative # of *Excludes AbCellera-initiated and Trianni-license program. As of Dec 31, 2024. Historical results are not necessarily indicative of future results. 96 6 76 39 14 37 42 5 4 Understood to be Progressing In Progress AbCellera Leading or Co-Leading Work Partner Leading Work AbCellera Started Transferred to Partner Clinical Development Preclinical Development Discovery Not Expected to Progress Not Expected to Progress

 
16 CO PY RI GH T © A BC EL LE RA Large diversified exposure to next-gen antibody therapies. *As of December 31, 2024 AbCellera-Initiated Programs* started across these therapeutic areas27 100% human health n = 27 Partner-Initiated Programs with Downstream Participation* started are diversified across these therapeutic areas 96 91% human health: target antigen known n = 87 9% animal health n = 9 21% neurology 6% infectious disease 5% ophthal- mology 4% other 17% immunology & inflammation 47% oncology 30% oncology & immunology T-cell engagers 56% undisclosed GPCRs & ion channels n = 8 n = 15 infectious disease pandemic response 4%10% undisclosed other n = 3 n = 1 Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e

 
17 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Operating expenses reflect investments, predominantly in R&D; partly offset by $29M in revenue. Operating Expenses USDRevenue USD 20242023 $175.7M $167.3M -$8.4M 20242023 $14.2M $12.8M -$1.4M 20242023 $61.0M $72.7M +$11.7M RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMINLICENSING RESEARCH FEES MILESTONES 2024 $26.3M 2023 $38.0M $28.8M $1.5M $1.0M$35.6M Milestones Licensin g Research fees

 
18 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Net loss of $163M; equivalent to ($0.55) per share (basic & diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC AND DILUTED 2023 2024 ($146.4M) ($162.9M) Post-production ❑ Move “Q” labels down

 
19 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e Approximately $653M in total cash, equivalents, and marketable securities. Cash Flows USD * Restricted cash (including restricted cash in other assets) ($51M) Other INVESTING FINANCING FX $469M Marketable Securities $156M Cash & Equivalents $27M* $627M Marketable Securities $173M Marketable Securities (net) OPERATINGDec 31, 2023 $27M* $133M Cash & Equivalents $788M ($109M) $121M $13M ($3M) $653M Dec 31, 2024

 
20 CO PY RI GH T © A BC EL LE RA Fu ll Y ea r 2 02 4 Bu si ne ss U pd at e THANK YOU

 
v3.25.0.1
Cover
Feb. 27, 2025
Cover [Abstract]  
Document Type 8-K
Entity Registrant Name AbCellera Biologics Inc.
Document Period End Date Feb. 27, 2025
Entity Incorporation, State or Country Code A1
Entity File Number 001-39781
Entity Address, Postal Zip Code V5Y 1G6
Entity Central Index Key 0001703057
Amendment Flag false
Entity Address, Address Line One 150 W 4th Avenue Vancouver, BC
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
City Area Code (604)
Local Phone Number 559-9005
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares
Trading Symbol ABCL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
AbCellera Biologics (NASDAQ:ABCL)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025 Plus de graphiques de la Bourse AbCellera Biologics
AbCellera Biologics (NASDAQ:ABCL)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025 Plus de graphiques de la Bourse AbCellera Biologics